FATE THERAPEUTICS INC Additional Paid in Capital, Common Stock
FATE THERAPEUTICS INC (FATE) had Additional Paid in Capital, Common Stock of $248.96 million as of 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2017-03-16
- 2016-12-31: Additional Paid in Capital, Common Stock $248.96M.
- 2016-09-30: Additional Paid in Capital, Common Stock $193.24M.
- 2016-06-30: Additional Paid in Capital, Common Stock $182.26M.
- 2016-03-31: Additional Paid in Capital, Common Stock $181.44M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2016-12-31 | $248.96M 10-K · filed 2017-03-16 |
| 2016-09-30 | $193.24M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $182.26M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $181.44M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $180.39M 10-K · filed 2017-03-16 |
| 2014-12-31 | $140.71M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |